CD274 and neoplasm: Taken together, combined with other preclinical studies showing that PD-1 blockade might also enhance tumor responses to other forms of immunotherapy [48,49], we reveal that PD-1/PD-L1 blockade presents a promising immunotherapeutic approach for EBV+DLBCL.